EVMN
No price yet
Announcements
Nothing here yet
Daily updates
- Evommune reported positive Phase 2a proof-of-concept results for EVO301 in moderate-to-severe atopic dermatitis. The trial met its primary endpoint, with 55% mean EASI improvement at Week 12 versus 22% for placebo (p<0.01) after two doses. EVO301 suppressed Th2, Th1, Th17, and Th22 pathways with a favorable safety profile, supporting a planned Phase 2b trial in mid-2027.Oct 1, 2026
- Evommune's Phase 2b EVO756 trial failed to meet efficacy endpoints in atopic dermatitisSep 9, 2026
FDA designations
Nothing here yet
News
- Evommune's Phase 2b EVO756 trial missed its primary and secondary endpoints in atopic dermatitis, leading to termination of the programSep 9, 2026
- Evommune initiated a Phase 2b trial of the MRGPRX2 inhibitor EVO756 for migraine preventionJul 31, 2026
- Evommune reported positive topline Phase 2b results for EVO756 in chronic spontaneous urticariaJun 29, 2026
- Evommune reported positive top-line results from a Phase 2a proof-of-concept trial of EVO301 in moderate-to-severe atopic dermatitisFeb 10, 2026